Professor Nicholas Tonks and colleagues at Cold Spring Harbor Laboratory say that they've seen a promising response to PTP1B inhibitors in mouse models of Rett syndrome, an X-linked disorder that generally kills boys early in life while severely disrupting the lives of girls.
Researchers at the University of Southampton have developed a small molecule which they refer to as "Compound 14" that deceives cells into thinking they have run out of energy--spurring on glucose uptake and increasing metabolism.
CRISPR/Cas9 tech and gene editing has emerged as a hot field in biotech, spurring a full slate of startups. Now one of the pioneers in the field has supervised a project that points to a more efficient use of technology in editing T cells.
A research team at Massachusetts General developed a gene therapy to deliver a protein that demonstrated signs of successfully reining in recurrent ovarian cancer in a mouse model for the disease.
An assistant professor of neurosurgery at The University of Florida (UF) College of Medicine has demonstrated a novel therapeutic strategy to significantly slow the growth of an aggressive brain tumour.
A new animal study carried out by researchers in France has helped demonstrate the role that mast cells play in spurring wet age-related macular degeneration and other chronic eye conditions.
A meta-analysis of data from more than 160,000 diabetics has offered some convincing data to support the theory that PPARγ activation by glitazones--either Avandia (GlaxoSmithKline's rosiglitazone) or pioglitazone--offers significant protection against Parkinson's disease. And the researchers who did the study say that their work should help accelerate work in the field.
Promising research conducted by Dr. Ernest Wright and Dr. Jorge Barrio, both of UCLA's Jonsson Comprehensive Cancer Center, show two types of sodium-dependent glucose transports known as SGLT1 and SGLT2 are actively involved in glucose uptake into tumors. And that makes them prime targets for drug investigators.
Yale scientists successfully tried out Pfizer's rheumatoid arthritis drug Xeljanz (tofacitinib) on a small group of people suffering from severe, treatment-resistant eczema, highlighting its added promise after the drug also demonstrated its potential in fighting two other skin conditions.
A group of investigators at Stanford has spotlighted iron-containing microglia--a scavenger cell that can become inflammatory--in postmortem examinations of the brains of Alzheimer's victims.
With the Alzheimer's Association International Conference underway in Washington, DC, there's been a big focus on the late-stage pipeline. But scientists at NYU Langone Medical Center were focused on new animal data that they say supports work on a new group of antibodies that can tackle two of the chief culprits behind the brain-damaging disease.
Scientists coated nanospheres of paclitaxel with a peptide shell that stays intact as it travels through the circulatory system and is then split open by enzymes known to spur metastasis. The drug can then be directed straight to cancer cells at 16 times the regular dose, halting tumor growth.
As investigators focused on Alzheimer's try to address the disease as early as possible, new research on a prime biomarker for the disease helps shed some light on early indications of developing cases--as well as just how devilishly difficult this field is.
Mutations in an X chromosome gene called TEX11 have been tapped as the likely cause of about 1% of all cases of male infertility, which could help begin to explain the origins of infertility at a time when genetic counseling is becoming increasingly popular.
New research published in The Journal of Neuroscience by a John Hopkins team led by Paul Fuchs points to a new therapeutic approach to tackling a causal mechanism for age-related hearing loss.
Vascular ischemia is the progressive narrowing and blockage of blood vessels. The buildup of fats in the blood, known as hyperlipidemia, can increase the likelihood of a heart attack or stroke. Recent work at Temple University's School of Medicine (TUSM) found this process is regulated by caspase-1 and inhibiting this protein may stimulate new blood vessels to re-oxygenate tissue that become starved of oxygen during a period of vascular ischemia.
A global team of scientists working with Johns Hopkins' Jordan Green has developed a new nonviral gene therapy for brain cancer, successfully testing it in the lab in cell lines as well as rat models for the disease.
A research consortium involving investigators at the University of Oxford has developed a gene therapy for cystic fibrosis that has demonstrated some proof-of-concept results that are encouraging new work on a hopefully more effective approach.